首页> 外文OA文献 >Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.
【2h】

Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.

机译:通过使用重组免疫毒素B3(Fv)-PE38的框架交换,将单克隆抗体B3的Fv快速人源化。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

B3(Fv)-PE38 is a recombinant single-chain immunotoxin in which the Fv region of carcinoma-specific antibody B3 is fused to a truncated form of Pseudomonas exotoxin (PE). The efficacy of monoclonal antibody B3 and B3 immunotoxins in cancer therapy and diagnosis may be limited by the human anti-mouse response. Here we describe the humanization of the Fv of B3(Fv)-PE38 by "framework exchange." The variable domains of the heavy (VH) and light (VL) chains were aligned with their best human homologs to identify framework residues that differ. Initially, 11 framework residues in VH and six in VL were changed by site-specific mutagenesis to human residues and introduced simultaneously into a preassembled single-chain Fv expression cassette. Six VH and five VL residues that differ were not changed because they were buried, in the interdomain interface, or previously found to result in decreased affinity when mutated. This basic design resulted in some 20-fold loss of activity. Changing VL residues at the interdomain interfacial position 100 and at the buried position 104 to the human sequence increased the activity 8-fold. Changing VH residue at position 82b from the human sequence back to that of the mouse restored the activity 2- to 3-fold to the full binding and cytotoxic activity of the mouse sequence. Humanized B3(Fv)-PE38 lost immunogenic epitopes recognized by sera from monkeys that had been immunized with B3(Fv)-PE38.
机译:B3(Fv)-PE38是重组单链免疫毒素,其中癌特异性抗体B3的Fv区融合到截短形式的假单胞菌外毒素(PE)。单克隆抗体B3和B3免疫毒素在癌症治疗和诊断中的功效可能会受到人类抗小鼠应答的限制。在这里,我们通过“框架交换”描述了B3(Fv)-PE38 Fv的人源化。重链(VH)和轻链(VL)的可变域与它们的最佳人类同源物对齐,以鉴定不同的构架残基。最初,通过位点特异性诱变将VH中的11个框架残基和VL中的6个框架残基更改为人残基,并同时引入到预组装的单链Fv表达盒中。六个不同的VH和五个VL残基没有改变,因为它们被埋在域间界面中,或者先前发现它们在突变时导致亲和力降低。此基本设计导致活动损失约20倍。将域间界面位置100和掩埋位置104处的VL残基改变为人序列,将活性提高了8倍。将位置82b的VH残基从人的序列改回为小鼠的VH残基,可将活性恢复到小鼠序列的完全结合和细胞毒性活性的2至3倍。人源化B3(Fv)-PE38失去了已被B3(Fv)-PE38免疫的猴子的血清识别的免疫原性表位。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号